History of Changes for Study: NCT00644124

Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-C

Latest version (submitted May 5, 2016) on ClinicalTrials.gov

- A study version is represented by a row in the table.
- Select two study versions to compare. One each from columns A and B.
- Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The S applies to the Protocol section of the study.
- Click "Compare" to do the comparison and show the differences.
- Select a version's Submitted Date link to see a rendering of the study for that version.
- The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study v
- Hover over the "Recruitment Status" to see how the study's recruitment status changed.
- Study edits or deletions are displayed in ~~red~~.
- Study additions are displayed in green.

Study Record Versions

Version	A	B	Submitted Date	Changes
1	◉	◉	March 21, 2008	None (earliest Version on record)
2	○	○	April 25, 2008	Study Status

Version	A	B	Submitted Date	Changes
4	○	○	September 19, 2008	Study Status, Outcome Measures and Study Identification
5	○	○	March 3, 2009	Study Status
6	○	○	March 10, 2009	Recruitment Status, Contacts/Locations and Study Status
7	○	○	August 30, 2011	Sponsor/Collaborators, Study Status, Study Identification and References
8	○	○	January 3, 2012	Recruitment Status, Study Status and Study Design
9	○	○	May 5, 2016	Arms and Interventions, Study Status, Study Design and Study Identification

Compare

Comparison Format: ◉ Merged ○ Side-by-Side

Scroll up to access the controls

Study NCT00644124
Submitted Date: March 21, 2008 (v1)

Study Identification

Unique Protocol ID: TCD10173

Brief Title: Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin

Official Title: A Phase I Open-Label Dose-Escalation Study of Intravenous Aflibercept (AVE000 Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Pa Hodgkin's B-Cell Lymphoma

Secondary IDs: AVE0005
EudraCT 2007-003737-16

Study Status

Record Verification:	March 2008
Overall Status:	Recruiting
Study Start:	March 2008
Primary Completion:	
Study Completion:	
First Submitted:	March 21, 2008
First Submitted that Met QC Criteria:	March 21, 2008
First Posted:	March 26, 2008 [Estimate]
Last Update Submitted that Met QC Criteria:	March 21, 2008
Last Update Posted:	March 26, 2008 [Estimate]

Sponsor/Collaborators

Sponsor:	Sanofi
Responsible Party:	
Collaborators:	Regeneron Pharmaceuticals

Oversight

U.S. FDA-regulated Drug:

U.S. FDA-regulated Device:

Data Monitoring: No

Study Description

Brief Summary: The purpose of this study is to determine the selected dose of aflibercept when it
CHOP treatment (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Predniso
Methotrexate) administered every 2 weeks or every 3 weeks, in non Hodgkin B-c
determine how the body handles aflibercept when it is administered with R-CHOP

Detailed Description:

Conditions

Conditions: Lymphoma, Non-Hodgkin

Keywords: Non-Hodgkin's lymphoma
angiogenesis inhibitors
CHOP protocol

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 1
Interventional Study Model:	Parallel Assignment
Number of Arms:	
Masking:	None (Open Label)
Allocation:	Non-Randomized
Enrollment:	50 [Anticipated]

Arms and Interventions

Intervention Details:

Drug: aflibercept
in combination with standard treatment R-CHOP

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.